Read by QxMD icon Read

Gelfand and intravenous

Parmanand Singh, Silvia González-Ramos, Marina Mojena, César Eduardo Rosales-Mendoza, Hamed Emami, Jeffrey Swanson, Alex Morss, Zahi A Fayad, James H F Rudd, Jeffrey Gelfand, Marta Paz-García, Paloma Martín-Sanz, Lisardo Boscá, Ahmed Tawakol
UNLABELLED: (18)F-FDG accumulates in glycolytically active tissues and is known to concentrate in tissues that are rich in activated macrophages. In this study, we tested the hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF), a clinically used cytokine, increases macrophage glycolysis and deoxyglucose uptake in vitro and acutely enhances (18)F-FDG uptake within inflamed tissues such as atherosclerotic plaques in vivo. METHODS: In vitro experiments were conducted on human macrophages whereby inflammatory activation and uptake of radiolabeled 2-deoxyglucose was assessed before and after GM-CSF exposure...
September 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Reo Yasuma, Valeria Cicatiello, Takeshi Mizutani, Laura Tudisco, Younghee Kim, Valeria Tarallo, Sasha Bogdanovich, Yoshio Hirano, Nagaraj Kerur, Shengjian Li, Tetsuhiro Yasuma, Benjamin J Fowler, Charles B Wright, Ivana Apicella, Adelaide Greco, Arturo Brunetti, Balamurali K Ambati, Sevim Barbasso Helmers, Ingrid E Lundberg, Ondrej Viklicky, Jeanette Hw Leusen, J Sjef Verbeek, Bradley D Gelfand, Ana Bastos-Carvalho, Sandro De Falco, Jayakrishna Ambati
Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1...
2016: Signal Transduction and Targeted Therapy
Melanie E Gelfand, Rodney A Gabriel, Robert Gimlich, Sascha S Beutler, Richard D Urman
Assessing the depth of anesthesia and reducing intraoperative awareness has become a focus of much technology development and research in the field of anesthesia. Bispectral index (BIS) is the most widely utilized technology that uses electroencephalogram to provide a measurement of anesthetic depth. There are no definitive guidelines on when BIS should be used. Our aim was to assess actual patterns of intraoperative use of BIS by anesthesia professionals. We retrospectively collected intraoperative data on 55,210 surgical cases at a tertiary care hospital...
April 2017: Journal of Clinical Monitoring and Computing
Carolyn Bevan, Jeffrey M Gelfand
While not all multiple sclerosis (MS) relapses require treatment, relapses that are bothersome or that impair function should prompt consideration of timely treatment to restore function and minimize disability. Patients with suspected MS relapses should be evaluated to confirm the diagnosis, exclude other causes of neurological dysfunction, and identify potential triggers for relapse or pseudo-relapse, such as urinary tract infections, fever, or metabolic derangements. The diagnosis of an MS relapse is clinical, but MRI may be useful for confirmation and to evaluate for multifocal disease activity...
April 2015: Current Treatment Options in Neurology
Frederic Fahey, Katherine Zukotynski, David Zurakowski, Robert Markelewicz, Anthony Falone, Marie Vitello, Xinhua Cao, Frederick Grant, Laura Drubach, A Hans Vija, Manojeet Bhattacharya, Xinhong Ding, Zvi Bar-Sever, Michael Gelfand, S Ted Treves
PURPOSE: To determine if the minimum administered radiopharmaceutical activity for hepatobiliary scintigraphy can be reduced while preserving diagnostic image quality using enhanced planar processing (EPP). METHODS: A total of 40 infants between 10 and 270 days old (body mass 2.2 - 6.5 kg) had hepatobiliary scintigraphy during the period 2004 - 2010 following the intravenous administration of either (99m)Tc-mebrofenin (18 patients) or (99m)Tc-disofenin (22 patients)...
December 2014: European Journal of Nuclear Medicine and Molecular Imaging
Sarosh R Irani, Jeffrey M Gelfand, Brianne M Bettcher, Neel S Singhal, Michael D Geschwind
IMPORTANCE: This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)-complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody-associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases. OBSERVATIONS: This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48-73 years) treated with rituximab...
July 1, 2014: JAMA Neurology
Maaz S Mohiuddin, Jordan K Abbott, Nicholas Hubbard, Troy R Torgerson, Hans D Ochs, Erwin W Gelfand
No abstract text is available yet for this article.
June 2013: Journal of Allergy and Clinical Immunology
Erwin W Gelfand, Hans D Ochs, William T Shearer
This Current perspectives article will review and highlight the importance of accurate diagnosis of patients who have failed to produce specific antibodies to naturally encountered foreign proteins or polysaccharides or after vaccination and the appropriate institution of immunoglobulin replacement therapy. The field of primary immunodeficiency disease (PIDD) has expanded remarkably since the early descriptions 6 decades ago. With greater recognition and advanced cellular and molecular diagnostic technology, new entities and single-gene defects in patients with PIDD are rapidly being defined...
April 2013: Journal of Allergy and Clinical Immunology
Erwin W Gelfand
New England Journal of Medicine, Volume 367, Issue 21, Page 2015-2025, November 2012.
November 22, 2012: New England Journal of Medicine
Jamie D Murphy, Harold J Gelfand, Mark C Bicket, Jean-Pierre P Ouanes, Kanupriya K Kumar, Gillian R Isaac, Christopher L Wu
OBJECTIVES: Pruritus may be a significant problem for patients in the postoperative period. There are many options for the treatment of pruritus including intravenous (IV) naloxone. However, it is not clear whether the use of IV naloxone may also affect analgesia or other opioid-related side effects. The authors have performed a systematic review to further examine this issue. METHODS: Systematic literature searches of the National Library of Medicine's PubMed and EMBASE databases were conducted using terms related to postoperative use of IV naloxone...
July 2011: Journal of Opioid Management
Amar Dhand, Kazuma Nakagawa, Seema Nagpal, Jeffrey M Gelfand, Anthony S Kim, Wade S Smith, Tarik Tihan
BACKGROUND: Ventricular free wall rupture is a fatal complication of myocardial infarction (MI). Although described in MI patients who receive thrombolytic therapy, this complication is not well known in ischemic stroke patients who receive intravenous (IV) t-PA. METHODS: Case report. RESULTS: We present a 93-year-old woman with an acute onset of a right middle cerebral artery syndrome in the setting of subacute MI. IV t-PA was administered and she subsequently developed asystolic arrest and died...
October 2010: Neurocritical Care
Christa Prins, Erwin W Gelfand, Lars E French
Since they were first administered to patients with antibody deficiency disorders over 50 years ago, human intravenous immunoglobulin preparations have been used successfully to treat a rapidly increasing number of autoimmune and inflammatory disorders, among which are a series of cutaneous autoimmune and inflammatory diseases. These include dermatomyositis, Kawasaki's disease, a number of autoimmune bullous diseases, severe adverse drug reactions, and other autoimmune and/or allergic conditions, such as atopic dermatitis...
2007: Acta Dermato-venereologica
Erwin W Gelfand, Kim Hanna
The incidence and severity of infusion-related adverse events (AEs) after infusions of IGIV-C, 10%, (Gamunex) at 0.14 mL/kg/min versus 0.08 mL/kg/min (standard rate) were compared. Patients with confirmed PID received two infusions 3-4 weeks apart with IGIV-C, 10% 400-600 mg/kg. Patients received their first infusion at 0.08 or 0.14 mL/kg/min and their second infusion 3-4 weeks later at the alternate rate, at an established step-wise rate increase. Ninety-seven of 100 patients remained valid for safety assessment...
May 2006: Journal of Clinical Immunology
Toshiyuki Koya, Katsuyuki Takeda, Taku Kodama, Nobuaki Miyahara, Shigeki Matsubara, Annette Balhorn, Anthony Joetham, Azzedine Dakhama, Erwin W Gelfand
RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCL5) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally...
August 2006: American Journal of Respiratory Cell and Molecular Biology
Erwin W Gelfand
The use of immune globulin intravenous (IGIV) as replacement therapy in immunodeficiency disease and as anti-inflammatory or immunomodulatory therapy in a variety of autoimmune and inflammatory diseases has expanded dramatically over the last decade. With this expansion, new challenges and concerns have emerged. As well, new products have been introduced while others have been discontinued. This evolution poses the important issue of product selection, choosing the "right" product for an individual patient...
April 2006: International Immunopharmacology
Erwin W Gelfand
Use of intravenous immunoglobulin (IVIG) therapy has expanded enormously in the past two to three decades, targeting a large number of autoimmune and inflammatory disorders as well as primary immunodeficiency disease, human immunodeficiency virus, and Kawasaki disease. Increased use, particularly at higher doses and in older patients, has presented certain challenges related to safety and tolerability. All IVIGs are not the same. They differ in manufacturing processes, methods of virus elimination, and final composition...
November 2005: Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society
Parthiv J Mahadevia, John Strell, Dan Kunaprayoon, Erwin Gelfand
OBJECTIVE: Human intravenous immunoglobulin manufactured with chromatography and caprylate methods (IGIV-C, 10%) was associated with a reduction in validated infections (pneumonia and sinusitis) compared with treatment with a licensed immunoglobulin product manufactured using standard solvent-detergent methods (IGIV-SD, 10%) in participants with primary humoral immunodeficiency disorder (PIDD). Our objective was to determine the cost-consequences of using IGIV-C instead of IGIV-SD. METHODS: Economic analysis of a double-blind, randomized, clinical trial was used...
July 2005: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Michael J Gelfand, Sara M O'hara, Lois A Curtwright, Joseph R Maclean
BACKGROUND: Radiopharmaceutical uptake of [(18)F]2-deoxy-2-glucose (FDG) in brown adipose tissue is noted on 15-20% of positron emission tomography (PET) scans in children and adolescents. One report suggests that moderate-dose oral diazepam can partly or completely block FDG uptake in brown adipose tissue. OBJECTIVE: To determine whether [(18)F]FDG uptake in brown adipose tissue can be adequately blocked by pre-medication other than moderate-dose oral diazepam...
October 2005: Pediatric Radiology
Anne Durandy, Volker Wahn, Steve Petteway, Erwin W Gelfand
Antibody or humoral immunodeficiencies comprise the largest group of primary immunodeficiency diseases. Since the first description of patients with low gammaglobulin levels more than four decades ago, a great wealth of information has been accumulated. Especially in the last several years, the application of molecular and genetic techniques has unraveled many of these disorders, identifying disorders of B cell development, failure of class switch recombination and abnormalities of specific antibody production...
March 2005: International Archives of Allergy and Immunology
No abstract text is available yet for this article.
December 1, 1949: New York State Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"